Pre-analytical stability of ocrelizumab in serum after delayed centrifugation of whole blood

[1] Bibinoglu Amirov C(2023)Ocrelizumab in pediatric multiple sclerosis Eur J Paediatr Neurol 43 1-5

[2] Saltik S(2024)Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability Drugs 84 285-304

[3] Yalcinkaya C(2008)Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research Trends Pharmacol Sci 29 186-191

[4] Tutuncu M(2022)Effect of Delayed Centrifugation on the Levels of NMR-Measured Lipoproteins and Metabolites in Plasma and Serum Samples Anal Chem 94 17003-17010

[5] Saip S(2012)The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies Mabs 4 623-631

[6] Siva A(2021)Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO Br J Clin Pharmacol 87 2511-2520

[7] Carlson AK(2017)Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis N Engl J Med 376 221-234

[8] Amin M(2020)The impact of pre-analytical variations on biochemical analytes stability: A systematic review J Clin Lab Anal 34 e23551-610

[9] Cohen JA(2014)Stability of 35 biochemical and immunological routine tests after 10 hours storage and transport of human whole blood at 21 degrees C Scand J Clin Lab Invest 74 603-220

[10] Danhof M(2017)Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis N Engl J Med 376 209-165

[1] Bibinoglu Amirov C(2023)Ocrelizumab in pediatric multiple sclerosis Eur J Paediatr Neurol 43 1-5

[2] Saltik S(2024)Drugs Targeting CD20 in Multiple Sclerosis: Pharmacology, Efficacy, Safety, and Tolerability Drugs 84 285-304

[3] Yalcinkaya C(2008)Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research Trends Pharmacol Sci 29 186-191

[4] Tutuncu M(2022)Effect of Delayed Centrifugation on the Levels of NMR-Measured Lipoproteins and Metabolites in Plasma and Serum Samples Anal Chem 94 17003-17010

[5] Saip S(2012)The assay design used for measurement of therapeutic antibody concentrations can affect pharmacokinetic parameters: Case studies Mabs 4 623-631

[6] Siva A(2021)Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO Br J Clin Pharmacol 87 2511-2520

[7] Carlson AK(2017)Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis N Engl J Med 376 221-234

[8] Amin M(2020)The impact of pre-analytical variations on biochemical analytes stability: A systematic review J Clin Lab Anal 34 e23551-610

[9] Cohen JA(2014)Stability of 35 biochemical and immunological routine tests after 10 hours storage and transport of human whole blood at 21 degrees C Scand J Clin Lab Invest 74 603-220

[10] Danhof M(2017)Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis N Engl J Med 376 209-165